159 related articles for article (PubMed ID: 9097267)
1. A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection.
Fernández JL; Rendo P; del Pino N; Viola L
J Viral Hepat; 1997 Mar; 4(2):113-9. PubMed ID: 9097267
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus RNA and long-term response to recombinant interferon-alpha 2b in patients with chronic hepatitis C.
Tanno H; Fernández JL; Rendo P; del Pino N; Viola L; Terg R; Pérez V
J Viral Hepat; 1995; 2(2):97-102. PubMed ID: 7493304
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment.
Campistol JM; Esforzado N; Martínez J; Roselló L; Veciana L; Modol J; Casellas J; Pons M; de Las Cuevas X; Piera J; Oliva JA; Costa J; Barrera JM; Bruguera M
Nephrol Dial Transplant; 1999 Nov; 14(11):2704-9. PubMed ID: 10534516
[TBL] [Abstract][Full Text] [Related]
4. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.
Reichard O; Norkrans G; Frydén A; Braconier JH; Sönnerborg A; Weiland O
Lancet; 1998 Jan; 351(9096):83-7. PubMed ID: 9439491
[TBL] [Abstract][Full Text] [Related]
5. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial.
Saracco G; Borghesio E; Mesina P; Solinas A; Spezia C; Macor F; Gallo V; Chiandussi L; Donada C; Donadon V; Spirito F; Mangia A; Andriulli A; Verme G; Rizzetto M
J Hepatol; 1997 Jul; 27(1):56-62. PubMed ID: 9252074
[TBL] [Abstract][Full Text] [Related]
6. Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection. Consensus Interferon Study Group.
Pockros PJ; Tong M; Lee WM; van Leeuwen DJ; Keeffe EB; Bala K; Killenberg PG; Foust RT; Rosenblate HJ; Payne KM; Fromm H; Lesesne HR; Black M
J Viral Hepat; 1998 Jul; 5(4):271-6. PubMed ID: 9751014
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection.
Yao GB; Fu XX; Tian GS; Xu DZ; Hao LJ; Huangfu YS; Su CX
J Gastroenterol Hepatol; 2000 Oct; 15(10):1165-70. PubMed ID: 11106097
[TBL] [Abstract][Full Text] [Related]
8. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
[TBL] [Abstract][Full Text] [Related]
9. Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: the role of interferon alpha 2b therapy.
Van Thiel DH; Caraceni P; Molloy PJ; Hassanein T; Kania RJ; Gurakar A; Friedlander L
J Hepatol; 1995 Nov; 23(5):503-8. PubMed ID: 8583136
[TBL] [Abstract][Full Text] [Related]
10. Treatment with interferon-alpha2b of naive non-cirrhotic patients with chronic hepatitis C according to viraemia and genotype. Results of a randomized multicentre study. The North West Italian Hepatological Group.
Saracco G; Ciancio A; Ghisetti V; Rocca G; Cariti G; Andreoni M; Tabone M; Roffi L; Calleri G; Ballaré M; Terreni N; Sartori M; Tappero GF; Traverso A; Poggio A; Orani A; Maggi G; Di Napoli A; Arrigoni A; Rizzetto M;
Eur J Gastroenterol Hepatol; 2001 Feb; 13(2):149-55. PubMed ID: 11246614
[TBL] [Abstract][Full Text] [Related]
11. Interferon plus ribavirin in chronic hepatitis C non-responders to recombinant alpha-interferon.
Bresci G; Parisi G; Bertoni M; Scatena F; Capria A
J Viral Hepat; 2000 Jan; 7(1):75-8. PubMed ID: 10718946
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C.
Di Marco V; Lo Iacono O; Cammà C; Almasio PL; Vaccaro A; Fuschi P; Giunta M; Fabiano C; Pagliaro L; Craxì A
J Med Virol; 1997 Jan; 51(1):17-24. PubMed ID: 8986944
[TBL] [Abstract][Full Text] [Related]
13. Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment.
Gürsoy M; Gür G; Arslan H; Ozdemir N; Boyacioglu S
J Viral Hepat; 2001 Jan; 8(1):70-7. PubMed ID: 11155154
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients.
Brouwer JT; Nevens F; Kleter B; Elewaut A; Adler M; Brenard R; Chamuleau RA; Michielsen PP; Pirotte J; Hautekeete ML; Weber J; Bourgeois N; Hansen BE; Bronkhorst CM; ten Kate FJ; Heijtink RA; Fevery J; Schalm SW
J Hepatol; 1998 Jun; 28(6):951-9. PubMed ID: 9672169
[TBL] [Abstract][Full Text] [Related]
15. Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and C: a multi-center, randomized, double-blind, placebo-controlled trial. Leich Study Group.
Niederau C; Strohmeyer G; Heintges T; Peter K; Göpfert E
Hepatogastroenterology; 1998; 45(21):797-804. PubMed ID: 9684137
[TBL] [Abstract][Full Text] [Related]
16. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
[TBL] [Abstract][Full Text] [Related]
17. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study.
Degos F; Pol S; Chaix ML; Laffitte V; Buffet C; Bernard PH; Degott C; Carnot F; Riffaud PC; Chevret S
Nephrol Dial Transplant; 2001 May; 16(5):1017-23. PubMed ID: 11328909
[TBL] [Abstract][Full Text] [Related]
18. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group.
Chemello L; Cavalletto L; Casarin C; Bonetti P; Bernardinello E; Pontisso P; Donada C; Belussi F; Martinelli S; Alberti A
Ann Intern Med; 1996 Jun; 124(12):1058-60. PubMed ID: 8633819
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients.
Pol S; Thiers V; Carnot F; Zins B; Romeo R; Berthelot P; Bréchot C
Kidney Int; 1995 May; 47(5):1412-8. PubMed ID: 7637270
[TBL] [Abstract][Full Text] [Related]
20. Genotype, serum level of hepatitis C virus RNA and liver histology as predictors of response to interferon-alpha 2a therapy in Japanese patients with chronic hepatitis C.
Mizokami M; Orito E; Gibo Y; Suzuki K; Ohba K; Ohno T; Lau JY
Liver; 1996 Feb; 16(1):23-7. PubMed ID: 8868074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
